Clinical Trial

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Study acronym: MajesTEC-10
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change).
Protocol Amendment History 2 changes
minor Completion pushed: 2027-03-03 -> 2028-01-13 2026-08-01
notable Primary completion moved earlier: 2027-02-28 -> 2025-06-03 2026-07-07
Trial Details
NCT Number NCT06425991
Lead Sponsor Janssen Research & Development, LLC
Conditions Multiple Myeloma
Enrollment 108 participants
Start Date 2024-06-07
Primary Completion 2025-06-03 (estimated)
Study Completion 2028-01-13 (estimated)
Updated on ClinicalTrials.gov 2026-07-31